The Burden of Opioid-Related Mortality in the United States

In this serial cross-sectional study published in JAMA, researchers found that the percentage of all deaths attributable to opioids increased 292% (from 0.4% to 1.5%) between 2001 and 2016, resulting in approximately 1.68 million person-years of life lost in 2016 alone (5.2 per 1000 population). The burden was particularly high […]

Learnings from the 2018 ISPOR Conference

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its annual conference in Baltimore, Md. on May 19-23, and Venebio consultant, Carlos H. Rojas-Fernandez, PharmD attended to gather insights on recent developments and trends in the industry. Rojas-Fernandez’s notes that there were a number of posters from Alkermes in the area […]

Surgeon General Releases Advisory on Naloxone, an Opioid Overdose-Reversing Drug

Today, U.S. Surgeon General Jerome M. Adams, M.D., M.P.H., urged more Americans to carry a lifesaving medication that can reverse the effects of an opioid overdose. The medication, naloxone, is already carried by many first responders, such as EMTs and police officers. The Surgeon General is now recommending that more individuals, including […]

PrescribeWellness Partners With Venebio to Help Local Pharmacies Address the Opioid Epidemic

PrescribeWellness and Venebio are working together to flight the opioid crisis. With network reach of over 200 million lives, PrescribeWellness is uniquely positioned to arm the most accessible healthcare professionals in the communities — pharmacists — with VOA, the only validated tool able to predict the likelihood of a life-threatening […]

New Hampshire Board of Medicine Recognizes Venebio Opioid Advisor™ as Approved Prescription Opioid Risk Assessment Tool

RICHMOND, Va. – January 31, 2018 – The New Hampshire Board of Medicine has approved Venebio Opioid Advisor™ (VOA™) as one of the state’s official risk assessment tools for opioid prescribing. New Hampshire state law requires that any opioid risk assessment tool be approved by the New Hampshire Board of Medicine. The […]

Study Revealing Highest Risk Profiles for Prescription Opioid Overdose Published in Pain Medicine

Comprehensive analysis of U.S. prescription opioid users and overdose cases further supports personalized approach to prescription of opioids. RICHMOND, Va. – January 15, 2017 – Individuals suffering from a substance use disorder (SUD) or depression are among those at highest risk for a serious prescription opioid overdose, according to a study […]

Study Validating Venebio Opioid Advisor’s Ability to Identify Patients at Risk of Prescription Opioid Overdose Published in Pain Medicine

Venebio Opioid Advisor is the only validated tool to predict the likelihood of a life-threatening opioid overdose with 90-percent accuracy. RICHMOND, Va. – January 15, 2017 – A study validating the strong performance of Venebio Group’s risk-screening tool for prescription opioid overdose — Venebio Opioid Advisor™ (VOA™) — has been published in the January […]

GAO Report: CMS Needs to Broaden Opioid Efforts to Identify and Address Those at Risk for Serious Harm

The Centers for Medicare and Medicaid Services (CMS) have focused for years on identifying opioid-treated beneficiaries at risk for serious harm such as overdose or addiction. Their approach has concentrated on patients prescribed high daily doses of opioids who also have indicators of opioid misuse or abuse, such as ‘doctor […]

Naloxone: An important tool, but not the solution to the opioid crisis

A recent study conducted at Brigham and Women’s Hospital showed that an opioid overdose patient who receives Naloxone and recovers from the overdose, and is subsequently discharged has a one-in-ten chance of dying within a year. The authors acknowledge that Naloxone is an important tool in fighting the opioid crisis, but does not provide […]

Are Prescription Drug Monitoring Programs (PDMPs) Sufficient to Lead Us out of the Opioid Crisis?

Although the adoption of PDMPs is an effort that holds promise, their ability to stem opioid overprescribing is inherently limited by the specific form of misuse that the programs aim to address. Read more in this insightful Brookings Op-Ed here.